Pneumococcal disease constitutes a major global health problem. Adults aged over 50
years and younger adults with specific chronic health conditions are at risk for invasive …

The global burden of pneumococcal diseases is high, with young children and adults≥ 50
years of age at highest risk of infection. Two types of vaccine are available for the prevention …

The incidence of pneumococcal diseases among adults increases with age. Therefore,
Germany's Standing Committee on Vaccination (Ständige Impfkommission, STIKO) has …

Background: Clinical trials and meta-analyses have produced conflicting results of the
efficacy of unconjugated pneumococcal polysaccharide vaccine in adults. We sought to …

Vaccination is the only public-health measure likely to reduce the burden of pneumococcal
diseases. In 2010, a group of European experts reviewed evidence on the burden of …

For decades, vaccination with the 23-valent polysaccharide pneumococcal vaccine (PPV23)
has been available for risk groups aged⩾ 2 years to prevent invasive pneumococcal …

Background Invasive pneumococcal disease (IPD) and pneumococcal pneumonia are
common and carry a significant morbidity and mortality. Current strategies to prevent …

Invasive pneumococcal disease (IPD) and pneumococcal pneumonia (PP) represent an
important health problem among aging adults and those with certain underlying pathologies …

Clin Microbiol Infect 2012; 18 (Suppl. 5): 7–14 Abstract Streptococcus pneumoniae causes
different types of acute, invasive and non‐invasive clinical infections, being the most …

Individuals< 2 years and≥ 50 years of age, as well as those with other specific risk factors,
are especially vulnerable to invasive pneumococcal disease (IPD). Conjugate vaccines …